本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

NGM Biopharmaceuticals Inc

1.54
+0.0000
成交量:- -
成交额:370.46万
市值:1.29亿
市盈率:-0.89
高:1.54
开:1.54
低:1.54
收:1.54
数据加载中...
2024/04/05

交易所摘牌声明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2024/04/05

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/04/05

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/04/05

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/04/05

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/04/05

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/04/05

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/04/05

重要事件披露

Form 8-K - Current report
2024/04/05

私有化交易

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
2024/04/05

私有化交易

Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
2024/04/04

[修订]年度报告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2024/03/23

SEC问询函

Form CORRESP - Correspondence
2024/03/22

私有化交易

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
2024/03/22

私有化交易

Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
2024/03/11

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/11

重要事件披露

Form 8-K - Current report
2024/03/08

私有化交易

Form SC 13E3 - Going private transaction by certain issuers
2024/03/08

私有化交易

Form SC TO-T - Tender offer statement by Third Party
2024/02/26

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/26

重要事件披露

Form 8-K - Current report